The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.
GASTROINTESTINAL MALIGNANCIES
Oesophageal cancer Loss of PTEN (phosphatase and tensin homologue deleted on chromosome 10) expression in oesophageal cancer is frequent, among other gene alterations characterizing this disease. Zhou et al. 1 found that overexpression of PTEN suppresses growth and induces apoptosis in oesophageal cancer cell lines, through downregulation of BCL2 resulting in changes in cell-cycle progression. Moreover, they have shown that PTEN gene therapy reduces tumour size in vivo, suggesting PTEN as an important biological marker. In addition, Hou et al. 2 investigated the relationship of PTEN status and cell sensitivity to chemotherapeutic drugs in vivo. Esophageal squamous cell carcinoma (ESCC) cells transfected with or without the wild-type PTEN were inoculated subcutaneously into nude mice. Both wild-type PTEN and cisplatin could inhibit tumour growth and induce cell apoptosis. Cisplatin had the strongest inhibitory effects on tumours produced by cells transfected with wild-type PTEN, indicating that PTEN can increase the in vivo sensitivity of ESCC cells to cisplatin. As further evidence of the importance of PTEN in oesophageal carcinogenesis, Ma et al. 3 have recently found a strong association of genetic polymorphisms in PTEN with high risk of ESCC.
In another study, immunohistochemistry (IHC) of 100 patients' tumours with ESCC revealed that cell division cycle 25 homologue A (CDC25A) and CDC25B phosphatases are strongly expressed in the cytoplasm of cancer cells. 4 Furthermore, due to the role of CDC25B in cell growth, Dong et al. 5 examined the levels of CDC25B antibodies (abs) in sera from 134 oesophageal squamous cell carcinoma patients and determined that they are higher compared with healthy subjects. Detection of CDC25B abs in combination with traditional tumour markers (that is, carcinoembryonic antigen, squamous cell carcinoma antigen, cytokeratin fragment 21-1 (CYFRA21-1)) resulted in an increased sensitivity of detection, with 64 .2% of patients testing positive for at least one of these markers. Moreover, high levels of CDC25B abs in sera were significantly associated with poor survival in advanced ESCC, suggesting that they may have a clinical utility in ESCC screening and diagnosis. 5 Cao et al. 6 investigated the role of protein tyrosine phosphatase, non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 protein expression is higher in normal para-cancerous tissues than in 20 ESCC tissues. By performing IHC, high and low expression of PTPN12 was found in 62.1% and 37.9% of ESCCs, respectively. Moreover, they demonstrated that patients with completely resected ESCC and tumours with high PTPN12 expression tumour had favourable survival compared with that of patients with low PTPN12, therefore proposing that PTPN12 can be used as an independent predictor of patient survival. 6 You et al. 7 evaluated the methylation levels of protein tyrosine phosphatase receptor type O (PTPRO) promoter as a potential biomarker in ESCC. Their analysis revealed hypermethylated PTPRO promoter status in 27 (75%) out of 36 primary tumours. No methylated PTPRO was observed in normal peripheral blood samples from 10 healthy individuals. In addition, in PTPROsilenced cell lines, expression was dramatically restored by treatment with the demethylating agent 5-azadC, confirming that DNA methylation is a mechanism regulating PTPRO expression and that aberrant methylation of the PTPRO promoter is directly responsible for transcriptional inactivation of its expression in ESCC cell lines. These findings suggest that PTPRO is a common target for epigenetic silencing via methylation in ESCC and that its methylation may be involved in oesophageal cancer tumourigenesis. 7 Moreover, Motiwala et al. 8 examined the levels of PTPRO methylation in blood cells, as the presence of detectable methylated promoter DNA in blood cells has been reported to indicate the presence of circulating cancer cells during the process of distant metastasis. Interestingly, PTPRO methylation occurred only in B-cell population of a subset of patients with chronic lymphocytic leukaemia, but not in normal B or T lymphocytes, indicating that methylated PTPRO in blood cells is cancer-specific. 8 Finally, a high frequency of PTPRO hypermethylation in primary tumours significantly correlated with tumour stage, indicating that PTPRO methylation may also be involved in invasion of ESCC. 7 Gastric cancer Insertion of cagA-protein from Helicobacter pylori into the gastric epithelial cells specifically binds and activates PTPN11 oncoprotein. 9 ,10 Activated PTPN11 induces cell growth and motility, 11 while deregulation of PTPN11 by cagA induces abnormal proliferation and migration of gastric epithelial cells that leads to gastric carcinogenesis. 12 Several studies detected aberrant DNA methylation of PTPN6 gene in gastric carcinomas. H. pylori infection led to a decrease in the methylation levels in PTPN6, 13 inconsistent with a previous report. 14 Yang et al. 15 reported that PTPN1 gene was amplified in gastric cancer tissues. With regards to the clinicopathological characteristics, PTPN1 was associated with tumour metastasis and tumour-node-metastasis stage, implicating its involvement in the development of gastric cancer. 16 As suggested, PTPN1 inhibitors may also be useful in the treatment of gastric cancer.
17
PTPN3 and PTPN4 are two closely related non-receptor tyrosine phosphatases that are expressed in human gastric cancer cells and tissue specimens.
18 PTPN3 dephosphorylates and cooperates with p38g, to form a complex that may increase Ras oncogenesis through post synaptic density protein (PDZ)-mediated direct binding. 19 The phosphatase activity of PTPN4 has been implicated in the regulation of cytoskeletal events. 20 Overexpression of PTPN4 in COS-7 (cells being CV-1 (simian) in Origin) cells decreased colony formation, inhibited cell growth and decreased saturation density of these cells. 21 Wu et al. 22 applied a reverse transcriptase-PCR-based protein tyrosine phosphatase (PTP) profiling approach to study PTP expression in human gastric cancer samples and identified 16 PTPs in the cancer tissues; only 6 of them (PTPN4, PTPRB, PTPRH, PTPRJ, PRPRN and PTPRZ) were expressed in gastric cancer tissue, while protein tyrosine phosphatase receptor type A (PTPRA) expression was significantly high in cancer tissues. The role of PTPRA) in gastric cancer might be linked to its biological role in integrin signalling, cell adhesion and activating the SRC family tyrosine kinases. [23] [24] [25] Reduced protein tyrosine phosphatase receptor type G (PTPRG) expression was detected by IHC in gastric tumour, 22 indicating that it might be a tumour-suppressor gene. In addition, differences in DNA methylation of PTPRG genes between primary tumour and metastatic lymph nodes of gastric cancer was also observed. 26 Until now, the detailed mechanisms underlying PTPRG-mediated cell signalling are not described.
In a mutational analysis study conducted by Wang et al., 27 protein tyrosine phosphatase receptor type T (PTPRT) was the most common mutated gene. Lee et al. 28 also detected a splicesite mutation in PTPRT gene in 1 of 48 gastric carcinomas and suggested that PTPRT phosphatase domain mutation may not have a role in the development of human cancers.
Finally, various reports have demonstrated overexpression of protein tyrosine phosphatase receptor type H (PTPRH), 29 Dualspecificity phosphatase 1 (DUSP1) 30 and phosphatase of regenerating liver (PRL-3) [31] [32] [33] [34] [35] in human gastric cancer, while Ooki et al. 36 showed that PRL-3 genomic amplification was associated with advanced stage.
Colorectal cancer A systemic mutational analysis of the tyrosine phosphatome in human colorectal cancer (CRC) has identified 83 somatic mutations in PTPRF, PTPRG, PTPRT, PTPN3, PTPN13 and PTPN14 genes. 27 Similarly, frameshift mutations have been depicted in PTPRA, PTPRS, PTPN5, PTPN13, PTPN21 and PTPN23, 37 while hypermethylation of PTPRO was showing microsatellite instability in colorectal tumours.
38
PTPN13 was shown to interact with the cytosolic domain of Fas, 39 while Miyazaki et al. 40 reported that overexpression of PTPN13 enhances sensitivity to Fas-mediated apoptosis. However, Yao et al. 41 demonstrated that expression of PTPN13 in 470% of colon cancers was related to resistance against Fas-mediated apoptosis in vivo and in vitro. These contradictory reports reveal that PTPN13 may possess dual role in colon carcinoma, either as an oncogene or as a tumour suppressor depending on the cellular context in which it is studied.
Lassmann et al. 42 evaluated distinct genomic DNA alterations using array comparative genomic hybridization and identified DNA amplification of PTPN1 in 22% of the CRC cases, with the highest percentage of changes in chromosomal-positive tumours. PTPN1 has been responsible for the activation and elevation of Src kinase activity in six human epithelial colon cancer cell lines. 43 Enhanced Src activity mediates signals and directs downstream activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Signal transducer and activator of transcription 3 (STAT3) has been shown to be activated in colon tumours and cell lines. 44, 45 Protein tyrosine phosphatase receptortype T (PTPRT) and protein tyrosine phosphatase receptor-type D (PTPRD) were shown to be able to regulate STAT3. 46, 47 As aforementioned, the mutation screen established that PTPRT was the most frequently mutated PTP in colorectal carcinomas. Zhang et al. 46 demonstrated that PTPRT specifically regulates phosphorylation of STAT3-Tyr 705 in CRC. Overexpression of PTPRT activity inhibited cell growth, suggesting a tumour-suppressor role. 27 In addition, paxillin, a direct substrate of PTPRT, can be dephosphorylated at Tyr88, which is involved in cell-cell adhesion. Mutated PTPRT could promote CRC tumourigenesis and cell migration, while studies demonstrated the development of colon tumours in PTPRT knockout mice. 48 It has been shown that PTPRD is frequently mutated in colon cancer. 47, 49 Mutations in PTPRD abrogate its ability to regulate STAT3, and loss of PTPRD function promotes cancer progression. 50 The role of PTPRA in CRC is poorly understood. PTPRA mRNA levels were found to be increased 70% in late stage (Dukes' D) colorectal tumours compared with adjacent normal colon mucosa. 51 Interestingly, overexpression of PTPRA increases substrate adhesion 25 and stromal invasion, 52 while its silencing suppresses anchorage-independent growth and induces apoptosis in colon cancer cell lines. 53 PTPRH is also abundantly expressed in human CRC specimens 54 and CRC cell lines. 29 PTPRH-deficient mice had normal intestinal tract, but loss of PTPRH inhibited tumourigenesis in mice with heterozygous mutation of the adenomatous polyposis coli gene, suggesting that PTPRH has a role in promoting the intestinal tumourigenesis. 55 Another significant phosphatase that modulated JAK-STAT pathway is the low molecular weight protein tyrosine phosphatases (LMW-PTP). Malentacchi et al. 56 observed an increase in the expression of LMW-PTP mRNA and protein levels in colon tumour samples; clinically, overexpression of LMW-PTP is generally associated with a proliferative phenotype and poor prognosis. 57 Here, overexpression of PRL-3 in primary colorectal tumours is associated with tumour aggressiveness. 58, 59 Jiang et al. 60 have shown that the loss of transforming growth factor-b (TGF-b) signalling leads to upregulation of PRL-3 expression and activation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB) pathway, which can promote epithelial-mesenchymal transition. 61 Further on, PTEN was downregulated by PRL-3 as shown by protein expression and IHC. [62] [63] [64] Moreover, DUSP1 is overexpressed in colon tumours; sporadic colorectal tumours and also found loss of heterozygosity at the PRPRJ locus in the sample of human CRC. 62 Pancreatic cancer More than half of pancreatic ductal adenocarcinoma tissues exhibit increased PI3K and AKT expression. [68] [69] [70] PH domain and Leucine-rich repeat protein phosphatases (PHLPP) levels are markedly reduced in human pancreatic ductal adenocarcinoma that have elevated AKT phosphorylation. 71 Studies have shown that PHLPP1 and PHLPP2 are able to terminate AKT signalling by directly dephosphorylating and inactivating AKT, resulting in great suppression of tumour growth. 72, 73 Although PTEN mutations are rarely found in pancreatic cancer, 74 it is important to note that PTEN loss of function may result in decreased sensitivity to apoptotic stimuli that could promote cellular over-growth and tumourigenesis. [75] [76] [77] Chow et al. 78 reported that TGF-b reduces PTEN expression and enhances the motility of pancreatic cancer cells through calcium-dependent PKCa. They also demonstrated that TGF-b downregulates PTEN via activation of nuclear factor (NF)-kB activity. 79 Mutations and changes of expression levels of TGF-b and SMAD4 proteins could be observed in pancreatic cancer tissues. [80] [81] [82] SMAD4 is a tumour suppressor able to mediate signals from a family of TGF-b ligands and via phosphorylation of receptor-activated SMADs (R-SMADs) proteins forming a trimeric complex. This complex translocates into the nucleus, binds to specific DNA sequence and activates gene transcription. 83 Protein phosphatase, Mg 2 þ /Mn 2 þ dependent, 1A (PPM1A/PP2Ca) was identified as a phosphatase that dephosphorylates the SXS motif of R-SMADs and terminates TGF-b signalling.
84
DUSP6 is a cytoplasmic DUSP that negatively regulates members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK (extracellular signal-regulated kinase), SAPK (stress-activated protein kinase)/JNK (c-Jun N-terminal kinase), p38), which are associated with cellular proliferation and differentiation. 85 DUSP6 dephosphorylates the active form of ERK2, which is constitutively expressed in pancreatic cancer cells. 86 Moreover, DUSP6 was reduced in invasive pancreatic carcinoma 86 and was missing in the majority of cultured pancreatic cancer cells. 87, 88 Finally, NF-kB pathway has also been implicated in pancreatic cancer. 89 Based on the classical NF-kB pathway cascade, the phosphorylated IKK (IkB kinase) can further phosphorylate IkB, an inhibitory subunit of the NF-kB that is proteolytically degraded upon phosphorylation. 90 Protein phosphatase 2A (PP2A) is required for signal-dependent activation of IKK. 91 Inhibition of PP2A triggers apoptosis in pancreatic cancer cell line through constant activation of the NF-kB pathway. 92 Li et al. 93 also suggested that treatment with cantharidin selectively inhibits PP2A and suppresses the growth of PANC-1 cells when c-Jun N-terminal kinase pathway is over-activated.
GENITO-URINARY TUMOURS
Renal cell and bladder cancer Alkaline phosphatases (ALPL) are a group of tissue-specific and tissue non-specific (TNAP) enzymes that have been previously implicated in suppressing meningiomas. 94 However, the relationship between ALPL levels and kidney cancer has not been established. The kidney expresses ALPL, which is used as a marker for organ function in patients' dialysis. 95 High serum levels of ALPL have been associated with paraneoplastic syndrome, as observed in 77 out of 365 patients with stage II-IV renal cell carcinoma (RCC), decreasing the 5-year survival to 35.7%. 96 ALPL is also used as a predictive marker for bone metastases, which is a common occurrence in patients with kidney and bladder cancer.
97
CDC25 phosphatases are frequently overexpressed in various malignancies, including RCC. 98 In renal cancer cells, downregulation of CDC25B induces a G2/M arrest and subsequent apoptosis with a concomitant reduction of the 14-3-3 protein.
Furthermore, inhibition of the CDC25B reduces the rate of renal cell migration and invasion. 99 Cpd5 is a selective inhibitor of CDC25 phosphatases, which acts as an anti-neoplastic agent for RCC. 100 Serine/threonine-protein phosphatase PP1-a catalytic subunit (PPP1CA) is involved in pRb dephosphorylation and ceramide accumulation induced by RAS. 101 Its role has been investigated in bladder cancer, as a potential marker for monitoring disease progression. Assessment of PPP1CA levels in urine was performed and correlated with standard cytology. Sensitivity of PPP1CA was 68.8% and the specificity was 62.7% (Po0.001). A positive correlation was found between bladder cancer grade and sensitivity, while for grade 1 and grade 2 tumours, PPP1CA and other evaluated markers were even superior to cytology.
102
PTPN21 stimulates the Src-EGF signalling axis, and its involvement in actin cytoskeleton, cell adhesion and in regulating the stability and recycling of the epidermal growth factor receptor (EGFR) has also been reported. PTPN21 is required for growth and motility of urothelial cancer cells in vitro, and its high expression in human bladder cancer tissue correlates with advanced tumour stage and invasiveness. Therefore, PTPN21 represents a novel biomarker and possible therapeutic target for bladder cancer. PTPN21 overexpression is thought to be an early step in urothelial cancer progression. In terms of expression in vivo, PTPN21 is absent from the normal bladder tissue, hyperplastic urothelium and urothelial papilloma, whereas its expression gradually increases from low grade to high grade urothelial carcinoma. 103 In a study in clear cell RCC (ccRCC), which originates from proximal tubular tissue, microsatellite alternations at chromosome 9p23-22 (D9S168) were more common at late stage renal cancer and associated with poor survival. The D9S168 alteration was associated with low expression of protein tyrosine phosphatase receptor delta (PTPRD), while IHC analysis revealed downregulation of PTPRD expression in ccRCC, suggesting it as a potential tumour suppressor. 104 The PTEN gene is important for the growth suppression of RCC, by inhibiting cell proliferation. In renal carcinoma cell lines and primary RCC, the frequency of loss of flanking markers around PTEN is 20-43%, and somatic intragenic mutations are less frequent (o17%). However, the rate of PTEN inactivation at the protein level may be more frequent than that identified at the genetic level. 105 A tissue microarray analysing 440 RCC specimens revealed that PTEN expression is typically decreased in RCC, 106 and represents an early step in renal cell carcinogenesis. A negative correlation between pAKT and PTEN was found in primary RCC. In terms of cellular distribution, PTEN was weaker at the cytoplasmic level and stronger in the nucleus in RCC compared with normal renal parenchyma. Multivariate analyses revealed that altered expression of PTEN was associated with adverse patient outcome. 107 However, interestingly in patient samples with invasive muscular bladder cancer, PTEN was found to be located in the cell cytoplasm and a positive correlation between PTEN and pAKT was observed. 108 In addition, lower PTEN expression was found in patients who died of metastases, within 5 years after surgery, compared with long-term survivors, indicating a critical role of PTEN in RCC progression. In particular, the pro-metastatic effects upon PTEN loss in RCC are achieved through Shc. 109 PTEN attenuation also mediates resistance to cisplatininduced apoptosis, through increasing levels of the cyclin kinase inhibitor p21. 110 In primary bladder cancers, loss of PTEN heterozygosity is seen in 23% of cases. Several portions of the gene were found deleted, namely that containing potential tyrosine and serine phosphorylation sites. Missense mutations in exon 1 and exon 2, which may inactivate the phosphatase activity of the PTEN gene, were detected in bladder cancer cell lines derived from advanced stage Phosphatases and cancer J Stebbing et al bladder cancers and were absent from a cell line derived from a lower stage cancer. However, in vivo analysis in 33 bladder cancer specimens, including the 25 T3/T4 bladder carcinomas, failed to replicate in vitro findings. Only 8% of the primary bladder cancer specimens are thought to harbour a mutation or homozygous deletion in PTEN, raising the possibility that another gene in close proximity to PTEN is the actual primary target of inactivation. 111 In invasive bladder cancer, loss of PTEN in combination with altered p53 has adverse consequences and serves to identify a subgroup of patients with particularly aggressive disease, which are candidates for mammalian target of rapamycin (mTOR) inhibitors as a therapeutic strategy. 112 Finally, a recent mouse study found that PTEN deletion only influenced urothelial morphology when coupled with a deletion of liver kinase B1 (LKB1), a tumour suppressor acting through tuberous sclerosis protein 1 (TSC1). 113 Cyclin-dependent kinase-associated protein phosphatase (KAP) is expressed at the G1/S transition of the cell cycle and forms a complex with cyclin-dependent kinase 2 (CDK2). KAP is overexpressed in RCC, while a correlation with higher histological grade has been shown. 114 KAP promotes growth of RCC and confers resistance to anti-tumour necrosis factor-a-induced apoptosis by preventing caspase-3 activation. Furthermore, HEK293 cells overexpressing KAP have a greater ability of cell invasion. In vivo xenograft models confirmed that KAP induces tumourigenicity, with significantly larger xenograft tumours arising in nude mice inoculated with KAP over-expressing cells.
DUSP1 expression in renal cancer cells contributed to cell survival by attenuating the apoptosis-inducing signal cascade via JNK. DUSP1 is upregulated at the mRNA and at the protein level in low-grade bladder cancers, and its expression is inversely proportional to tumour grade, suggesting its relevance in the early stages of bladder cancer development.
115 DUSP9 expression correlates with the onset of kidney carcinoma, where it is downregulated at both the mRNA and at the protein level. Patients with tumours exhibiting low DUSP9 expression had significantly worse overall survival, indicating that DUSP9 expression has an independent predictive value. 116 HER-2-positive bladder cancers also exist and carry an adverse prognosis. Suppression of interferon-g is often used as a therapeutic approach in bladder cancer patients. This treatment is probably less effective in HER-2 overexpressing/amplified tumours due to upregulated Src homology 2-containing PTPN11 signalling. A dysfunction in PTPN11 regulation can cause abnormal cell growth and induce different kinds of cancers.
117 PTPN11 is mainly expressed in the collecting duct system and in distal tubules and hardly in glomeruli and proximal tubules. Its abundance was evident in rare renal tumours, such as chromophobe RCC or oncocytoma. 118 Finally, the inhibitor of apoptosis stimulatory protein phosphatase (iASPP) is a key inhibitor of p53. iASPP is important for bladder cancer cell proliferation, 119 where it has been shown that iASPP knock down inhibits cell growth and colony formation. 120 Prostate cancer PTEN mutations were firstly identified in multiple advanced cancers, including prostate cancer (PCa), leading to its potential role as a tumour-suppressor gene. 121, 122 Shortly, different groups confirmed that PTEN inactivation was frequently shown in prostate cell lines, xenografts as well as primary PCa. [123] [124] [125] [126] Homozygous deletion of PTEN in the prostate epithelium resulted in malignant prostate carcinoma displaying its association with cancer progression. 127 Biological function studies showed that by dephosphorylation of PIP 3 to PIP 2 , PTEN tumour suppressor acts as a vital negative regulator of the PI3K/AKT/mTOR pathways affecting many aspects of cellular activity, including growth and survival, whereas loss of PTEN leads to activation of these signalling cascades. 77, 128 In AKT-dependent mouse model, mTOR inhibition reserved prostate intraepithelial neoplasia through the modulation of apoptosis and HIF-1 related pathways. 129 Inhibiting PDK1, which activates AKT and S6K, prevented the development of prostate adenocarcinoma induced by PTEN heterozygous in mice. 130 It is now clear that tumours harbouring PTEN loss are highly dependent on PI3K/AKT signal for survival and proliferation. Meanwhile, inhibition of these kinases can converse the effects of PTEN loss. 131 Therefore, pharmacological targeting PI3K/AKT and mTOR kinases have provided potential therapeutic importance in PTEN-null cancers, including PCa. Indeed, several molecules, including PI3K inhibitor (XL147), AKT inhibitor (perifosine) and mTOR inhibitors (CCI-779 and RAD001), are under clinical development. 132 Furthermore, PTEN loss was shown to have an important role in the survival crosstalk between PI3K/AKT and androgen receptor (AR) in PCa progression. Upon acute androgen ablation in human PCa cell line LNCaP, PTEN inactivation displayed increased activity of the PI3K/AKT axis, indicating a possible compensating phenomenon across PI3K/AKT and AR signalling. 133, 134 PCas with PTEN null relapsed after androgen withdrawal and enjoyed the capability of growth in the absence of androgen. Moreover, global analysis of genomic alterations elicited by homozygous PTEN deletion identified genes associated with cancer metastasis. 135 In addition, it has been reported that PTEN can suppress the transcriptional activity of AR and cell proliferation induced by androgen as well as prostate-specific antigen, whereas androgens prevented PCa cells from PTEN-dependent apoptosis in the presence of AR. 136 Similar evidence described that PTEN can directly interact with AR resulting in an inhibition of the AR nuclear translocation and an increase of the AR degradation in a PI3K/AKTindependent manner, while in PTEN-null context both AR expression and activity were elevated compared with wildtype MEFs. 137 Collectively, PTEN loss may lead to a gain-offunction of AR in both PI3K/AKT-dependent and -independent environment. Coordinately, loss of PTEN and intensified AR may contribute to tumourigenesis and androgen refractory PCa.
Pro-apoptotic protein Par-4 was shown to be essential for PTENdependent apoptosis, while AKT can directly bind to Par-4 and inhibit its activity through phosphorylation resulting in the survival of PCa cells. 138 Recent studies demonstrated that Par-4 inactivation associates with PTEN loss in a high percentage of human prostate carcinomas. Similar to PTEN-heterozygous mice, Par-4-null mice only developed benign prostate lesions, whereas simultaneous Par-4 loss and PTEN haploinsufficiency caused invasive PCa in mice through activating AKT signalling as well as NF-kB pathway. 139 Protein phosphatase 1 (PP1) and PP2A are two major classes of serine/threonine protein phosphatases involved in many different cellular processes, including survival, cell cycle and apoptosis, through dephosphorylation of key regulators, such as PKA, AKT, PKC and glycogen synthase kinase 3.
140,141 PP2A comprises of several subunits: scaffolding, catalytic and regulatory. Each subunits of PP2A exists in at least two isoforms.
142,143 PPP2CA levels were found decreased in majority of androgen-independent PCa cell lines and in cancer lesions as compared with the adjacent normal/benign tumour tissues. 144 PPP2R2A, a potential tumoursuppressor gene, was found commonly deleted among PCa with homozygous deletions and no significant association between common single nucleotide polymorphisms of PPP2R2A and sporadic PCa. These findings suggested that it may have an important role in PCa tumourigenesis on somatic levels. 145 In PCa, caveolin-1 was shown to bind to and inhibit PP1 and PP2A resulting in AKT activity enhancement, indicating an important interplay involving both the phosphatases in tumourigenesis. 146 Recent studies showed that PP1 can regulate AR protein stability and cellular localization via dephosphorylation of Ser-650. 147 2,4,3 0 ,5 0 tetramethoxystilbene, a synthetic trans-stilbene analogue, was able to induce PP2A activation leading to inhibition of AKT. This, in turn, stimulated expression of cell-cycle inhibitor p27(kip1) 148 A failed recruitment of PP2A-Ba by TGF-b type 1 receptor was suggested to be partly responsible for TGF-b abundance in malignant prostate cells. 149 Moreover, PP2A activity was decreased in androgen-independent PCa cells (C4-2) compared with androgen-dependent LNCaP cells, whereas inhibition of PP2A enabled LNCaP cells to grow in an androgendeprived condition. 150 Sodium selenate, a specific seleniumcontaining compound, was identified as a PP2A activator, which significantly augmented the activity of PP2A, thereby inhibiting VEGF (vascular endothelial growth factor)-induced growth and vessel branching of endothelial cells and obstructing tumour neovascularization. This anti-angiogenisis effect via PP2A allowed it into a phase 1 study in patients with castration-resistant PCa and results showed a similar effect to other anti-angiogenic agents. 151, 152 The cell division cycle 25 (CDC25) families are DUSPs functioning in activation of CDKs, which in turn modulate cell-cycle progression. In mammalian cells, three isoforms have been identified: CDC25A, CDC25B and CDC25C. 153 CDC25A and CDC25B were shown to be overexpressed in human PCa tissues and high CDC25B level was associated with high Gleason scores and aggressiveness in PCa. 154, 155 These two different studies also demonstrated that CDC25A can suppress androgen-responsive promoter via physically interacting with AR, whereas CDC25B can function as a coactivator of an AR in a hormone-dependent manner in LNCaP. Similarly, CDC25C expression was elevated in PCa in comparison with normal prostate tissues and its spliced isoform was also found to be correlated with increased growth in PCa. 156 Theaflavin, a black tea polyphenol, can cause G2/M phase arrest in PC-cells by inducing cyclin kinase inhibitor p21 (waf1/cip1) and inhibiting CDC25C and cyclin B. 157 Taken together, several studies have shown that CDC25 family phosphatases are important players in PCa progression and may provide potential therapeutic targets in PCa.
SHP1, an SH2 domain-containing protein tyrosine phosphatase, was detected in normal prostate, benign prostate hyperplasia, prostate epithelial cells and well-differentiated adenocarcinoma, whereas diminished SHP1 expression was observed in malignant prostate tissue and poorly differentiated advanced PCa. [158] [159] [160] [161] Moreover, SHP1 overexpression decreased PC-3 cell proliferation. 159 Tassidis et al. 161 demonstrated that the expression of SHP1 mRNA and protein in two human PCa cell lines, LNCaP and PC-3, were at different levels. In this study, silencing SHP1 in LNCap, which expresses high amount of endogenous SHP1 protein, exhibited an increase in cellular proliferation and cyclin D1. By contrast, in PC-3 cells, with low endogenous level of SHP-1 expression, overexpression of SHP-1 resulted in a decrease in proliferation and cyclin D1. A recent study showed that depletion of SHP1 in PC-3 cells caused G1 phase cell-cycle arrest by increasing p27 protein stability, due to its capability of regulating PI3K/AKT pathway and CDK2 activity. This indicated that SHP1 may have a role in the regulation of cell-cycle progression. 162 SHP2, an SH2 domain-containing protein tyrosine phosphatase sharing homology with SHP-1, is also expressed in PCa cell lines, including PC-3, DU145, LNCaP and LNCap-IL6 þ (interleukin-6 þ ) as well as patient specimens with PCa. SHP2 staining from 122 patients showed that low cytoplasm intensity associated inversely with prostate volume while staining in the nucleus was positively correlated with extracapsular extension. This implicated that SHP-2 ablation in the cytoplasm correlated with enhanced tumour growth. 163 However, other studies reported that SHP2 may act as a proto-oncogene product by increasing Ras-MAPK signalling. 164 
GYNAECOLOGICAL TUMOURS
Endometrial cancer There are two main types of endometrial cancer (EC) namely type-I, which is oestrogen receptor and progesterone receptor positive with low grade and type-II with clear-cell or serous morphology and high grade. [165] [166] [167] Currently, endocrine and chemotherapy are being used to treat type-I EC. 168 Although most clinical trials and treatment regimens do not stratify patients according to type, research at molecular level have identified distinct genetic alterations and signalling pathways between the two types. For example, type I cancer frequently has deregulated PI3K/PTEN/AKT pathway and loss of PTEN function while type-II has alterations in P53 and/or P16 pathways along with overexpression and amplification of HER2.
PP2A is a well-known tumour suppressor that inhibits RAF-MEK-ERK pathway by inhibiting activity of ERK and RAF besides inhibiting the downstream signalling of RAS pathway via dephosphorylation and inhibition of c-Myc, RALA and AKT. Depending on the type of cancer, this function of PP2A has been shown to be mediated by regulatory b subunits. 169 On the contrary, somatic missense mutations in PPP2R1A, which encodes the a-isoform of the PP2A scaffolding subunit, were demonstrated in high-grade serous endometrial tumours. 170 Constitutive activation of MAPK pathway is known to have an important role in EC and as DUSP6 can negatively regulate ERK2, Chiappinelli et al. 171 studied its methylation status in EC. They identified that silencing of DUSP6 is uncommon and unlikely to cause activation of MAPK pathway in EC. On the other hand, LMW-PTP was studied and a significant association was identified in low-grade EC with genotypes carrying the C allele along with high concentration of S isoform. 172 Finally, Allard et al. 173 studied the role of phosphatases in determining racial inequality in EC. Using microarray, they identified phosphoserine phosphatase (PSPH), which is essential for the synthesis of L-serine, and designated phosphor-serine phosphatase-like (PSPHL) as the most overexpressed genes in EC in African-Americans when compared with Caucasians.
Cervical cancer
The role of PP1 in tumour metastasis was studied by knock down of PP1 and its regulator NIPP1 in HeLa cells. Knock down of PP1 prevented migration of HeLa cells by inhibiting Cdc42 signalling pathway. 174 Zeng et al. 175 identified protein phosphatase 1 inhibitor 5 (IPP5) as a tumour suppressor in cervical cancer (CC); overexpression of mutant IPP5 in HeLa cells caused G2/M arrest both in vitro and in vivo via inhibition of ERK activation. Furthermore, Protein phosphatase 1, regulatory subunit 7 was shown to be significantly upregulated in metastatic CC patient samples after radiotherapy. 176 Moreover, hSHIP, a human SH2-containing inositol-5-phosphatase, has also been shown to inhibit growth and act as a tumour suppressor in CC. In vitro and in vivo studies by He et al. 177 have shown that stable overexpression of hSHIP induces S-phase arrest along with downregulation of AKT1/2 expression and phosphorylation, thereby inhibiting proliferation of CC HeLa cells. Taken together, PP1 and its regulatory subunits along with hSHIP have an important role in progression and therapeutic response in CC and can prove to be new therapeutic targets.
DUSP3 is known to dephosphorylate ERK1/2 and JNK1/2 MAPK kinases, which are key regulators of cellular differentiation, proliferation and apoptosis. In CC, knockdown of DUSP3 inhibited the growth of HeLa CC cells by increasing the expression of cyclindependent kinase inhibitor, p21 and inhibiting G1-S and G2-M cell-cycle transition. 178 This in vitro study was further supported by detection of increased expression and nuclear localization of DUSP3 in cervix cancer cell lines when compared with normal keratinocytes as well as in HPV (human papillomavirus)-positive cell lines when compared with HPV-negative cell lines. Furthermore, increased expression was identified in primary cervix cancer biopsies, including squamous cell carcinomas of unterine cervix and squamous intra epithelial lesions indicating potential use of DUSP3 as a new marker for progression of CC and as a new target for anticancer therapy. 179 Small-molecule inhibitors for DUSP3 have been developed that can inhibit enzymatic activity of DUSP3 at nanomolar concentrations while inhibiting the proliferation of cervix cancer cell lines without affecting proliferation of primary normal keratinocytes.
180
PP2B or serine/threonine phosphatase calcineurin was shown to promote CC cell proliferation by directly interacting and enhancing c-Jun protein stability and activity. This was confirmed in cervical tissue samples that showed decreased phosphorylation of c-Jun and enhanced total PP2B and c-Jun expression. 181 By contrast, PP2B was shown to be downregulated in malignant squamous carcinomas. 182 This inconsistency might be due to the small number of samples used in both the studies and requires further investigation. On the other hand, no mutations were identified in PPP2R1B gene, which encodes the beta isoforms of the subunit A of the PP2A between normal and cancer cell lines. 183 Expression of SHP-2 tyrosine phosphatase, was negatively associated with interferon-b expression in CC while its silencing inhibited growth of SiHa CC cell line by inducing expression of interferon-b. 184 Other phosphatases that can either inhibit or promote CC include hSHIP, a human SH2-containing inositol-5-phosphatase and DUSP-3, respectively. 177, 179, 180 Cancerous inhibitor of protein phosphatase 2A (CIP2A) was shown to be overexpressed in CC when compared with normal tissue by IHC and reverse transcriptase-PCR. More importantly, papillomavirus 16 E7 oncoprotein directly upregulated CIP2A expression, which could enhance proliferation and growth of CC cells by modulating c-Myc expression. 185 Finally, mutation and loss of PTEN has also been shown to drive tumourigenesis here, 186,187 as previously described.
Ovarian cancer Inactivation of PTEN by genetic mutation is well known in ovarian cancer (OC). 188 Several in vitro studies have shown that PTEN can regulate growth, invasion, migration and resistance to chemotherapy in OC. [189] [190] [191] [192] [193] Interestingly, PP2A has been shown to regulate PTEN; inhibition of PP2A decreased the expression of PTEN and enhanced phosphorylation of PTEN and AKT, causing increased migration/invasion of OC in fibrillar collagen, indicating PP2A as a tumour suppressor in OC. This was further supported by detection of decreased expression and activity of PP2A in OC tissue. 194 Expression of CIP2A, studied in 562 serous OC patients by IHC, showed strong cytoplasmic staining in 40% of the samples and was associated with high grade, advanced stage and poor outcome. 195 On the other hand, inhibition of PP2A was essential for the apoptosis induced by doxorubicin, 196 and translocation of PP2A to plasma membrane was essential for gonadotropinreleasing hormone (GnRH) antagonist cetrorelix-induced apoptosis in GnRH-responsive OC cells. 197 A study by Manzano et al. 198 evaluating the expression of 68 phosphatases in ovarian epithelial and cancer cell lines identified a 10-25-fold higher expression of DUSP1 in normal compared with malignant OC cell lines. This was confirmed by IHC staining in normal and OC specimens and was shown to be a critical factor in the progression of cancer.
PTPN13 was found to be increased both at RNA and protein level in Fas-resistant OC cell lines as well as in OC patient samples studied using tissue microarray. 199 Knock down of PTPN13 using small interfering RNA enhanced the sensitivity of SKOV3 cells to carboplatin, indicating that it can have a key role in carboplatin resistance. 200 In 106 OC patient samples, cell-cycle-related phosphatases, CDC25A and CDC25B, were found to be commonly expressed and were associated with poor prognosis independent of tumour grade, histotype, stage and residual tumour after surgery, thereby indicating potential role of these phosphatases to be used as prognostic factors. 201 Using northern blots and immunoblotting, Mok et al. 202 have shown that PTPN6 was overexpressed in seven of the eight ovarian epithelial carcinoma cell lines both at RNA and protein level along with overexpression in invasive ovarian epithelial cancer tissues.
Cisplatin is one of the most widely used drugs for treating OC. Sensitivity to cisplatin is known to be partly mediated by activation of p53 by checkpoint kinase 1 (CHK1). Protein phosphatase magnesium-dependent 1 (PPMD1) is known to deactivate p53 and Chk1 via dephosphorylation. Using cisplatinresistant cell lines, Ali et al. 203 showed knock down of PPMD1 can re-sensitize resistant cells to cisplatin by activating P53 and CHK1. Moreover, PPM1D was shown to be highly expressed at mRNA level in ovarian clear-cell carcinoma cell lines with amplification at 17q23.2 and was amplified in 10% of primary clear-cell carcinomas. 204 The role of protein phosphatases in cisplatin sensitivity was also studied by Bansal et al. 205 and they identified that patients with incomplete response to cisplatin had twofold lower PP2C levels when compared with those with complete response. This was confirmed by western blotting in platinumresistant OC cells. Moreover, genome-wide expression profiling of SK-OV-3 OC cells identified two regulatory subunits of PP2A as key mediators of sensitivity to cisplatin and knock down of each subunit by RNA interference made OC cells more responsive to cisplatin. 206 Polato et al. 207 studied the role of PRL-3 in OC and expression of PRL-3 mRNA was found to be higher in stage III OC samples when compared with stage I samples, and by using small interfering RNA, PRL-3 was shown to be important for growth of OC cells in vitro. 207, 208 Moreover, PRL-3 regulated migration and invasion of OC cells by interacting with integrin a1, inhibiting phosphorylation of integrin b1 and enhancing the downstream phosphorylation of Erk1/2. 209 In vivo mice studies have shown that monoclonal antibodies against PRL-3 can prevent both tumour growth and metastasis of OC cells making it a potential target for therapy in OC. 210 Finally, Tanyi et al. 211 identified decreased mRNA expression of phosphatidic acid phosphatase type 2A (PPAP2A, LPP-1) in OC, which is known to degrade lysophosphatidic acid that can promote tumour growth and metastasis.
OTHER TUMOURS
Lung cancer Several phosphatase (PTPases) have been identified to have a role in this malignancy. Omerovic et al. 212 performed a phosphatome RNAi screen in A549 lung cancer cells and ranked their effects on phosphorylation of AKT-Ser473. Although, PTEN appeared to be the main factor involved in inhibiting the oncogenic K-Ras, other phosphatases have been identified with similar potencies, including protein tyrosine phosphatase non-receptor type 2 (PTPN2) and protein tyrosine phosphatase non-receptor type J (PTPRJ). 212 PTEN protein expression was reduced or lost in 74% of lung tumours, with loss occurring more often in well to moderately differentiated tumours. In non-small-cell lung carcinoma (NSCLC), loss of PTEN protein expression occurs frequently, although the mechanism responsible for loss is not clearly attributable to deletion or epigenetic silencing. PTEN loss may also be a favourable prognostic marker, although further studies are needed to confirm this finding. 213 Scrima et al. 214 have suggested protein tyrosine phosphatase non-receptor type 13 (PTPN13) as candidate tumour-suppressor gene in NSCLC. This gene is frequently inactivated in NSCLC through somatic mutation (approximately 8%) or due to loss of protein expression (approximately 73%); PTPN13 negatively regulates anchoragedependent and anchorage-independent growth of NSCLC cell lines in vitro. 214 The CDC25 phosphatases are known to have an important role in cancer cell growth. Increased expression of CDC25B has been reported in tumours of different tissue origins, including NSCLC. Analysis of primary tumours and corresponding healthy lung tissues from 177 patients with NSCLC revealed an overexpression of CDC25B in 45.76% of the samples. Moreover, high expression of CDC25B correlated with positive expression of endothelin and with the number of intratumoural microvessels. Statistical analysis of survival data revealed that elevated CDC25B expression was significantly associated with shorter disease-free and overall survival, suggesting that CDC25B might have an important role in the angiogenic process and in determining the prognosis of patients with NSCLC. 215 Another protein known to have a role here is the DUSP1. It has been shown that downregulation of DUSP1 induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis, MAP kinase phosphatase activity, cell-cell signalling, growth factor and tyrosine-kinase receptor activity. Changes in the expression of some of these genes were due to modulation of c-Jun-N-terminal kinase and/or p38 activity by DUSP1. Another report showed that silencing of DUSP1 inhibits invasion and metastasis in NSCLC tumour. 216 Moreover, Chitale et al.
217 examined 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression and revealed that non-random patterns of copy number alterations are linked to EGFR and KRAS mutation status. They also discovered a striking association of EGFR mutations with under-expression of DUSP4, which is involved in negative feedback control of EGFR signalling. Clinically, DUSP4 loss has a significant impact on overall survival, further supporting its biological significance in lung adenocarcinomas.
DUSP4 loss also associates with p16/CDKN2A deletion and defines a distinct clinical subset of lung cancer patients. 217 Another phosphatase that seems to have a role in tumourigenesis is the protein tyrosine phosphatase non-receptor type 12 (PTPN12), by regulating cell adhesion and migration. However, the mechanism by which PTPN12 is regulated in response to oncogenic signalling is unclear. Zheng et al. 218 have shown that Ras induces ERK1/2-dependent phosphorylation of PTPN12 at Ser-571, which recruits peptidylprolyl cis/trans isomerase, NIMAinteracting 1 (PIN1) to bind to PTPN12. Isomerization of the phosphorylated PTPN12 by PIN1 increases the interaction between PTPN12 and focal adhesion kinase (FAK, PTK2), which leads to dephosphorylation of FAK-Tyr397 and the promotion of migration, invasion and metastasis of v-H-Ras-transformed cells. 218 Breast cancer Upregulation of PTPN1 was first described in human breast cancer (BC) cell lines overexpressing the neu oncogene. 219 Wiener et al.
220
reported a correlation between increased expression of PTPN1 and HER2 expression in human mammary tumours compared with normal breast tissue. Global deletion of PTPN1 either delayed or protected against mammary cancer in mice, depending on the HER2/Neu allele and mice strain used, 221, 222 suggesting that inhibition of PTPN1 may be a potential target for treating breast cancer. Targeted PTPN1 silencing in the mammary epithelium of either established mouse tumours or in human BC cells xenografts grown on HER2-positive mice has been shown to delay the early onset of formation of mammary tumours. 223 Recent studies indicate that PTPN13 may be an effective therapeutic target for the treatment of breast cancer. Lower levels of PTPN13 have been described in BC and metastatic tissue specimens 224 and increased expression of PTPN13 is associated with a favourable outcome in BC patients. 225 Overexpression of PTPN13 is sufficient to block the IRS-1 (insulin receptor substrate 1)/PI3K/MAPK pathway. 226 In addition, overexpression of PTPN13 in combination with anti-oestrogen treatment increased apoptotic cell death by the reduction of IGF-1 (insulin-like growth factor 1) induced IRS-1 and AKT phosphorylation.
227 PTPN13 can also inhibit tumour aggressiveness via the direct dephopshporylation of Src at Y419, 224 which is upregulated in tamoxifen-resistant ER-positive breast cancer patients. 228 New therapeutic routes using tamoxifen and SRC inhibitors are currently being examined. 229, 230 Loss of functional PTEN has been described in primary and metastatic breast tumours, 231, 232 resulting in hyperactivation of the PI3K pathway and an increase in cell proliferation. 233 Downregulation of PTEN activity and activation of the PI3K signalling pathway is associated with resistance to anti-oestrogen therapy. 234 Screening for PTEN mutations may identify BC patients who may benefit from treatment with AKT inhibitors. In this regard, BC cell lines with PTEN mutations were recently described to have increased sensitivity to the novel AKT inhibitor MK-2206. 235 Several other PTPs have a tumour-suppressor function in BC. PTPN12 has been shown to act as a potent tumour suppressor in triple-negative breast cancer cells and is more frequently inactivated in this BC subtype. Genetically silencing PTPN12 induces transformation and disrupts acinar formation in mammary epithelial cells. 236 Levels of cytoplasmic protein tyrosine phosphatase non-receptor type 9 (PTPN9) inversely correlate with STAT3 in BC tissue.
237 PTPN9 has been reported to inactivate STAT3 following EGFR dephosphorylation in breast cancer cells, 238 suggesting that PTPN9 may have a critical role in BC development.
A number of DUSPs are dysregulated in BC. The majority of breast carcinomas, including both poorly differentiated and metastatic stage diseases, express higher levels of DUSP1 compared with normal breast tissue. 65, 239 Studies suggest that inhibition of DUSP1 may be an effective therapeutic target against chemoresistance in BC patients. Increased expression of DUSP1 has been shown to correlate with decreased JNK activity. 239 Overexpression of DUSP1 in BC cell lines treated with chemotherapeutic agents, which target the JNK pathway, protects against apoptosis. Conversely, genetic or chemical silencing of DUSP1 enhances sensitivity to chemotherapeutics agents, 240 indicating that combination therapies that target this enzyme may be effective in the treatment of BC.
DUSP3, DUSP4 and DUSP5 also negatively regulate ERK signalling. DUSP4 upregulation has been described in BC tumours. 239 Deficiency of DUSP4 has been identified as a mechanism of neoadjuvant drug chemoresistance in breast cancer tumours. DUSP4 depletion is frequently found in chemotherapy refractory tumours, which are associated with increased cell proliferation and basal-like BC status. Overexpression of DUSP4 either in breast cancer cell lines or in BC xenograft mouse models increased chemotherapy-induced apoptosis, whereas depletion reduced chemosensitivity. 241 Upregulation of DUSP3 and DUSP5 has been reported in PMA (phorbol myristate acetate)-treated MCF-7 and BKBR3 breast cancer cell lines. Activation of the ERK1/2 pathway and accelerated growth arrest of BC cells has been observed following silencing of either DUSP3 or DUSP5, and overexpression of either phosphatase prevents growth inhibition and cell migration. 242 The novel phosphatase, VHZ (VH1-like (member Z)), encoded by the DUSP23 gene, is also associated with BC and has been identified in some invasive ductal and epithelia BC tumours. VHZ has been shown to localize to the centrosome and enhance G1/S cell-cycle progession, suggesting that this enzyme may be a potential chemotherapeutic target. 243 All three CDC25 isoforms (CDC25A, CDC25B, CDC25C) can regulate G 1 /S and G 2 /M cell-cycle transition.
153 CDC25A overexpression is associated with poor survival in BC patients. [244] [245] [246] In addition, CDC25A 263C/T and -51C/G polymorphisms that are Phosphatases and cancer J Stebbing et al associated with BC incidence and metastatic potential have been identified in BC patients, suggesting that CDC25A gene may be candidate marker for earlier diagnosis and target for BC therapy. 247 Recent studies have demonstrated increased Fox1 activity following CDC25A-indcued dephosphorylation of CDK2. Inhibition of CDC25A inhibits metastases in BC mouse models, suggesting that this phosphatase may be a potential target for advanced stages of the disease. 248 CDC25B is overexpressed in primary BC tumours, 249 although expression levels do not always correlate with an aggressive phenotype.
250 CDC25C splice variants have been found to shift or be elevated in BC cell lines, particularly in cell lines with multi-drug resistance or those treated with sublethal levels of genotoxic agents, 251, 252 suggesting that CDC25C splicing may be an additional regulatory event involved in cellular response to DNA damage in BC cells.
The oncogene SRC3, which is overexpressed or amplified in the majority of breast cancer tumours, 253 is a target for PP1. PP1 can block proteasome-dependent turnover of SRC-3 by dephosphorylation at Ser-101 and Ser-103, resulting in the stabilization of SRC-3. 254 Increased expression of mutated PP2A at the active phosphatase site pY307 has been reported in HER2/neu BC tumours, which significantly correlated with disease progression. 255 Loss of PP2A activity in HER2/neu-positive BC cells resulted in apoptotic cell death mediated by p38 MAPK caspase-3 PARP activation, 256 suggesting that this phosphatase may be a potential therapeutic target in BC.
MCF-7 cells carry an amplified PPM1D/Wip-1 gene and overexpress PPM1D phosphatase protein. Silencing PPM1D has been reported to enhance doxorubicin-induced apoptosis due to p53-mediated phosphorylation of Bax. 257 Overexpression of the Eyes Absent (EYA) family of proteins, which are essential co-activators of the Six1 family of homeobox transcription factors, have recently been reported to enhance the proliferartion, migration and invasiveness of BC cells. 258 Silencing of EYA2 in MCF-7 cells reverses the ability of Six1 to induce TGF-b signalling and induce characteristics associated with epithelialmesenchymal transition. 259 High-throughput screening assays have recently identified a series of specific small molecule EYA2 phosphatase inhibitors that may be useful for the development of future BC therapies. 260 Sarcomas Sarcomas are probably even more heterogenous than all the aforementioned tumour types.
261
PP2A has been identified in a protein array screen for interacting proteins with the Kaposi's sarcoma-associated herpesvirus (KSHV) LANA protein, which functions in latently infected cells as an essential component of KSHV replication and dysregulated cell growth. The subunits PP2A and PP2B, but not the catalytic subunit PP2C, were found to associate with LANA, suggesting that PP2A activity may be dysregulated in this sarcoma. 262 Alterations in PTEN expression have been described in several types of sarcoma. PTEN upregulation has been described in 80% of tissue samples from Kaposi's sarcoma biopsies, with 58% expressing phosphorylated PTEN. 263 PTEN losses and mutations are also a frequent occurrence in the malignant smooth muscle neoplasm, leiomyosarcoma. [264] [265] [266] SHP2 may be a promising therapeutic target for Kaposi's sarcoma. Constitutive activation of the viral G protein-coupled (vGPC) receptor, the Kaposi's herpes sarcoma virus associated chemokine, has been shown to result in the phosphorylation of SHP2. 267 The vGPCR contains a bona fide immunoreceptor tyrosine-based inhibitory motif that binds and constitutively activates Shp2. 268 Moreover, SHP2 is required for vGPCR activation of the MEK-ERK1/2 axis, the transcription factors AP-1 and NF-kB and vGPCR-induced endothelial cell migration.
267
PTPN13 is highly expressed in Ewing's sarcoma cell lines and in patient tumours, with higher expression levels in metastatic compared with primary tumours. PTPN13 has been found to associate with the aberrant transcription factor EWS-11 and is upregulated following overexpression of EWS-11. MK-STYX, which encodes for a MAP-kinase phosphatase-like protein, is also constitutively expressed in EFST and may be a putative target for therapy in this class of tumours. 270 
CONCLUSIONS
Phosphatases, like kinases, represent molecular switches that can turn on or off a variety of signalling pathways (Figure 1 ), resulting in abnormal cellular processes, including uncontrolled proliferation, differentiation, angiogenesis and metastasis. Thus far, a large number of phosphatases has been associated with the development and progression of different types of cancer (Table 1) . Further understanding and clarifying the involvement and role of phosphatases in signal transduction is likely to be helpful in developing targeted drugs to be used alone or in combination with other therapeutics for cancer treatment. Phosphatases and cancer J Stebbing et al
